AEMD — Aethlon Medical, Inc.

Aethlon Medical (AEMD) Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Balance: Approximately $7 million as of December 31, 2025.
• Operating Expenses: $2.06 million for Q3 2026, up 13.6% from $1.81 million in Q3 2025, primarily due to increased payroll costs, though offset by lower clinical trial expenses.
• Operating Loss: Increased to $2.06 million from $1.81 million year-over-year.
• Nine-Month Performance: Operating expenses decreased significantly to $5.36 million, down 27% from $7.34 million in the previous year, reflecting effective cost management.

2. Strategic Updates and Business Highlights

• Oncology Trial: Continued enrollment in the Australian trial for the Hemopurifier in patients with solid tumors not responding to immunotherapy. Cohort 1 has been completed, and Cohort 2 is underway with 2 out of 3 patients treated.
• Research and Development: Expansion of the extracellular vesicle (EV) research platform and compatibility studies with a simplified blood treatment system (SLAMB) to enhance clinical flexibility.
• Cost Management: Sustained reductions in operating expenses year-to-date, demonstrating a disciplined approach to financial management.

3. Forward Guidance and Outlook

• Trial Progress: The Data Safety Monitoring Board (DSMB) is expected to review safety data for Cohort 2 by late March 2026, with potential advancement to Cohort 3 shortly thereafter.
• Participant Pool: An uptick in interest from potential trial participants has been noted, which could expedite future enrollments.

4. Bad News, Challenges, or Points of Concern

• Operating Loss Increase: Despite cost management efforts, the operating loss has increased, indicating ongoing financial pressures.
• Regulatory Hurdles: Potential regulatory challenges with the SLAMB system, as it is not yet approved and will require additional compatibility testing.
• Focus on Australia: Aethlon has decided to concentrate solely on the Australian trial, foregoing potential opportunities in India, which may limit geographical diversification of clinical data.

5. Notable Q&A Insights

• Cohort 2 Treatment Schedule: Patients in Cohort 2 receive two Hemopurifier treatments within the same follow-up period as Cohort 1, allowing for better evaluation of treatment efficacy.
• SLAMB System Integration: Transitioning to the SLAMB system could simplify administration and reduce invasiveness for patients, but will require thorough testing to ensure compatibility.
• Future Trials: Cohort 3 is considered necessary to evaluate the efficacy of three treatments, based on prior research suggesting that more frequent treatments may yield better outcomes.
• Operational Focus: The company remains committed to executing the Australian trial effectively before considering additional trials elsewhere, emphasizing a cautious approach to expansion.

Overall, Aethlon Medical is making progress in its clinical trials while maintaining a focus on cost management. However, challenges remain in terms of increasing operational losses and navigating regulatory pathways for new systems.